M&C in the news - Neurotech patents in Europe: Methods, medical devices, and the EPC exclusion

As neurotechnology continues to advance rapidly, questions around how best to protect innovation are becoming ever more pressing. 

In a recent article for pharmaphorum, Robert Lind and Eve McGlynn examine the unique challenges of protecting neurotech under the European Patent Convention, where medical and treatment methods are excluded from patentability. Unlike pharmaceuticals, devices cannot rely on new therapeutic uses alone, making structural innovation key to securing protection, highlighting the importance of careful patent drafting to help innovators navigate Europe’s evolving neurotech landscape.

Read the full piece below.

Subscribe to receive more articles like this here.

As neurotechnology evolves, clear and compliant patent drafting will be essential to achieve commercial success in the European market.

pharmaphorum.com/...